FORMA Therapeutics, Inc.

131 articles about FORMA Therapeutics, Inc.

• 

  Novo Nordisk Shells Out $1.1B for Forma, Sickle Cell Drug

  9/1/2022

  Novo Nordisk has entered into an agreement to acquire Forma Therapeutics for $1.1 billion. Forma’s lead development candidate, etavopivat, is being developed for sickle cell disease.

• Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

  8/5/2022

  Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today reported financial results for the second quarter ended June 30, 2022.

• Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia

  8/2/2022

  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Forma Therapeutics, Inc. (Nasdaq: FMTX) today announced that they have entered into an exclusive, worldwide license agreement to develop, manufacture and commercialize olutasidenib, an oral, small molecule inhibitor of mIDH1 being investigated for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML) and other malignancies.  

• Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022

  7/29/2022

  Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD), prostate cancer and other rare hematologic diseases and cancers, today announced that it will release second quarter 2022 financial results Friday, August 5, 2022.

• Forma Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

  7/12/2022

  Forma Therapeutics Holdings, Inc. today announced that its Board of Directors granted to Agustín Melián, M.D. and Linea Aspesi non-qualified stock options of 118,000 and 59,000 shares, respectively, of its common stock.

• Forma Therapeutics Announces Appointment of New Executive Team Members

  6/30/2022

  Agustín Melián, M.D. to be named Executive Vice President, Head of Research and Development and Linea Aspesi to be named Senior Vice President, Chief Human Resources Officer.

• Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences

  6/10/2022

  Updated results from the completed Phase 1 study of etavopivat in patients with sickle cell disease (SCD).

• Forma Therapeutics to Present at the Jefferies Healthcare Conference

  6/3/2022

  Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will participate in the Jefferies Healthcare Conference taking place June 8-10, 2022. Forma will present on June 9, 2022 at 2:00 p.m. Eastern Daylight Time (EDT).

• Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) Day

  5/26/2022

  Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD), prostate cancer and other rare hematologic diseases and cancers, will hold a virtual R&D Day today to provide a comprehensive update on its pipeline and strategic vision.

• Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

  5/6/2022

  Forma Therapeutics Holdings, Inc. today reported financial results for the first quarter ended March 31, 2022.

• Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022

  4/29/2022

  Forma Therapeutics Holdings, Inc. today announced that it will release first quarter 2022 financial results Friday, May 6, 2022.

• Forma Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

  3/1/2022

  Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today reported financial results for the year ended December 31, 2021.

• Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference

  2/8/2022

  Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference.

• Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee

  1/13/2022

  Forma Therapeutics Holdings, Inc. today announced that Arturo Molina, M.D., M.S., F.A.C.P., has been elected to serve on the company’s board of directors and R&D committee.

• Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

  1/7/2022

  Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference.

• Forma Therapeutics’ Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia

  12/16/2021

  Forma Therapeutics Holdings, Inc. today announced the company's investigational oral, selective mIDH1 inhibitor combined with azacitidine yielded durable complete remission (CR) or CR with partial hematologic recovery (CRh) responses with favorable tolerability in patients with the mIDH1 form of acute myeloid leukemia (AML).

• Forma Therapeutics’ Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease

  12/11/2021

  Forma Therapeutics Holdings, Inc. announced etavopivat, the company's investigational oral, once-daily, selective pyruvate kinase-R activator, significantly improved anemia and red blood cell health with a favorable tolerability and safety profile in patients with SCD.

• Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease

  12/9/2021

  Forma SCD Trend Report: The State of Transition survey reveals 62% of patients found the transition experience “moderately or very challenging” and 73% of physicians state there are a lack of transition guidelines and protocols in their practice or institution.

• 

  BioSpace Movers & Shakers, Dec. 3

  12/3/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

•  Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer

  11/30/2021

  Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer.